Explanipedia

Hypoxic conditioning in Parkinson’s disease: randomized controlled multiple N-of-1 trials Open

Jules M. Janssen Daalen, Marjan J. Meinders, Federica Giardina, Soania Mathur, Philip N. Ainslie , et al. · 2025

Preclinical evidence suggests positive symptomatic and neuroprotective effects of hypoxic conditioning in Parkinson’s disease (PD). This study (NCT05214287) investigated the safety, feasibility, short-term symptomatic and downstream effect…

From Hopelessness to Hope: Addressing Demoralization in Parkinson's Disease Open

Bradley McDaniels, Ellen Bradley, Gregory M. Pontone, Kuhan Pushparatnam, Soania Mathur , et al. · 2025

Background Demoralization is a pervasive yet under‐recognized syndrome that manifests as profound hopelessness, helplessness, loss of motivation and purpose, and impaired coping capacity. Affecting over one‐third of individuals in medical …

Using Principles of Cognitive Behavioral Therapy to Treat Anxiety in Parkinson's Disease Open

Alice Cronin‐Golomb, Bradley McDaniels, Soania Mathur, Gregory M. Pontone, Gretchen Reynolds , et al. · 2025

Anxiety significantly affects persons with Parkinson's disease (PwP), often emerging in the prodromal phase before the onset of symptoms and persisting throughout the disease's course. It is among the most disabling, stigmatizing, and unde…

Patient Empowerment for Those Living with Parkinson’s Disease Open

Soania Mathur, Sarika Mathur · 2024

Parkinson’s disease (PD) poses a number of challenges for individuals, affecting them physically, mentally, emotionally, and socially. The complex nature of PD necessitates empowering patients to address their unique needs and challenges, …

Digital biomarkers for non-motor symptoms in Parkinson’s disease: the state of the art Open

Jules M. Janssen Daalen, Robin van den Bergh, Eva M. Prins, Mahshid Sadat Chenarani Moghadam, Rudie van den Heuvel , et al. · 2024

Digital biomarkers that remotely monitor symptoms have the potential to revolutionize outcome assessments in future disease-modifying trials in Parkinson’s disease (PD), by allowing objective and recurrent measurement of symptoms and signs…

Cognitive Symptoms in Cross-Sectional Parkinson Disease Cohort Evaluated by Human-in-the-Loop Machine Learning and Natural Language Processing Open

Jennifer L. Purks, Lakshmi Arbatti, Abhishek Hosamath, Amy W. Amara, Karen E. Anderson , et al. · 2024

Nearly one-third of participants with PD, even early in the disease course, report cognitive symptoms as among their most bothersome problems. Online verbatim reporting analyzed by human-in-the-loop curation, natural language processing, a…

Randomized controlled trial of intermittent hypoxia in Parkinson’s disease: study rationale and protocol Open

Jules M. Janssen Daalen, Marjan J. Meinders, Soania Mathur, Hieronymus W. H. van Hees, Philip N. Ainslie , et al. · 2024

In Their Own Words: Fears Expressed by People with Parkinson’s Disease in an Online Symptom Database Open

Sneha Mantri, Jennifer L. Purks, Daniel Kinel, Lakshmi Arbatti, Abhishek Hosamath , et al. · 2024

Parkinson’s disease (PD) carries substantial psychosocial burden. Using a database of responses by people with PD reporting up to five “most bothersome problems,” we identified 225 fear-based verbatims, which were organized using the frame…

Perspectives of People At-Risk on Parkinson’s Prevention Research Open

Jessi L. Keavney, Soania Mathur, Karlin Schroeder, Ray Merrell, Sergio A. Castillo‐Torres , et al. · 2024

The movement toward prevention trials in people at-risk for Parkinson’s disease (PD) is rapidly becoming a reality. The authors of this article include a genetically at-risk advocate with the LRRK2 G2019 S variant and two patients with rap…

Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease Open

Daniel Weintraub, Connie Marras, Amy W. Amara, Karen E. Anderson, Lana M. Chahine , et al. · 2024

Background Early identification of subjective cognitive complaints (SCC) in Parkinson's disease (PD) may improve patient care if it predicts cognition‐related functional impairment (CFI). Objectives The aim was to determine the cross‐secti…

Perspectives of People At-Risk on Parkinson's Prevention Research Open

Jessi L. Keavney, Soania Mathur, Karlin Schroeder, Ray Merr, Sergio A. Castillo‐Torres , et al. · 2023

The movement toward prevention trials in people at-risk for Parkinson’s is rapidly becoming a reality. The authors of this article include a genetically at-risk advocate with the LRRK2 G2019S variant and two patients with rapid eye m…

What Patients Say: Large-Scale Analyses of Replies to the Parkinson’s Disease Patient Report of Problems (PD-PROP) Open

Connie Marras, Lakshmi Arbatti, Abhishek Hosamath, Amy W. Amara, Karen E. Anderson , et al. · 2023

Background: Free-text, verbatim replies in the words of people with Parkinson’s disease (PD) have the potential to provide unvarnished information about their feelings and experiences. Challenges of processing such data on a large scale ar…

Self-Image in Women with Parkinson’s Disease Open

Soania Mathur, Kristi LaMonica, Helen Matthews, Kat Hill · 2023

There is a fundamental gap in knowledge in how Parkinson’s disease manifests and affects women throughout their hormonal life cycle, resulting in unmet needs and adversely impacting women’s quality of life. A set of questionnaires was deve…

Internal tremor in people with Parkinson’s Disease: Demographic characteristics and comorbid symptoms Open

Lana M. Chahine, Lakshmi Arbatti, Abhishek Hosamath, Amy W. Amara, Karen E. Anderson , et al. · 2023

How Vacations Affect Parkinson's Disease Open

Jules M. Janssen Daalen, Jessica Hubbers, Mirmohsen Sharifi Bonab, Soania Mathur, Dick H. J. Thijssen , et al. · 2022

Contains fulltext : 290897.pdf (Publisher’s version ) (Open Access)

Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: study rationale and protocol Open

Jules M. Janssen Daalen, Marjan J. Meinders, Federica Giardina, Kit C. B. Roes, Bas C. Stunnenberg , et al. · 2022

Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Patient’s Perspective Open

Soania Mathur, Jon Stamford · 2021

There is an urgent unmet need in the Parkinson’s disease community—advanced therapies to modify the inevitable decline that occurs in those affected by this progressive neurodegenerative disease for which there is no cure. This will requir…

Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective Open

Diane Stephenson, Reham Badawy, Soania Mathur, Maria Tome, Lynn Rochester · 2021

The burden of Parkinson’s disease (PD) continues to grow at an unsustainable pace particularly given that it now represents the fastest growing brain disease. Despite seminal discoveries in genetics and pathogenesis, people living with PD …

What People with Parkinson’s Disease Want Open

John Andrejack, Soania Mathur · 2020

Parkinson’s disease is an incurable, progressive neurodegenerative disease. This condition is complicated by the varying symptoms in individuals who differ in age of onset, symptoms, progression of disease, response to treatment and progno…

The power of the Parkinson's patient according to Tom Isaacs: a call to action Open

Soania Mathur · 2018

For me, one of the biggest challenges and yet also the biggest opportunity is galvanizing people who live with Parkinson's from day-to-day to engage with their condition. If everyone with Parkinson's were to communicate their experiences o…

Rising to the Challenges of Clinical Trial Improvement in Parkinson’s Disease Open

Soania Mathur, Steve DeWitte, Israel Robledo, Tom Isaacs, Jon Stamford · 2015

Background: Despite an urgent need for new medications, clinical trials in Parkinson’s have a relatively low rate of success. Although many reasons have been proposed for this, the opinions of patients and scientists, the two principal sta…

Soania Mathur YOU? Author Swipe